ProgressPotentialAndPossibilities

Dr. Nag Vaidyanathan, Ph.D. is Chief Technology Officer and EVP at Duck Creek Technologies (https://www.duckcreek.com/), a leading provider of core system solutions to the Property and Casualty and general insurance industries, where via the company’s enterprise software-as-a-service solution, pioneering digital transformation, insurance carriers are able to navigate uncertainty and capture market opportunities faster than their competitors. Dr. Vaidyanathan is responsible for the execution of Duck Creek’s current and emerging product roadmaps while ensuring the adoption of proven software development patterns, architecture standards and frameworks. He is a senior IT leader who loves to work in the intersection of diversity of people and what they bring to work, ways of working, infrastructure, and different technology landscapes. Previously, Dr. Vaidyanathan was accountable for all application delivery and operations, digital transformation, infrastructure, IT security, and data at OneMain Financial as part of their Executive team. He also served roles at both Allstate and Dansk Bank. Dr. Vaidyanathan serves as a Board advisor for the Indo-American Community services organization to run programs serving the Indo-American community across the country, and as a member of the Board of Pratham, Chicago chapter, serving underprivileged kids in India. Dr. Vaidyanathan also serves as a mentor via the Menttium Corporation and engages in different mentoring events as a way of giving back. Dr. Vaidyanathan has his PhD from Copenhagen Business School, Department of Digitalization, an MTech in Engineering Management form Manipal Institute of Technology, and an MBA, in Finance and Strategy, from DePaul University.

Dr. Dumazedier Kabasele, MD, is the Founder of the Dumazedier Kabasele Foundation, a non-profit organization with a goal to raise awareness, and prevent, treat and beat stroke in the Democratic Republic of Congo (DRC). Dr. Kabasele earned his medical degree from the International Christian University in DRC, completed a special training fellowship in Neurology / Electro-Neurophysiology from the National Institute of Mental Health and Neuroscience in India, studied and trained in specialty stroke care at Hopistal Du Cinquantenaire (http://www.padiyathmedicitykinshasa.com/) in Kinshasa, DRC, where he currently practices care, and is completing a degree in Applied Health and Public Health at Brigham Young University (Idaho). Dr. Kabasele is highly passionate about vascular neurology and paralytic stroke care. He has appeared in various TV shows and talks to raise awareness about various neurological disorders in the DRC and believes strongly in transforming the world by giving hope to people and help them to have a better health and life.

Dr. Elizabeth Fowler, Ph.D., J.D., (https://www.cms.gov/about-cms/leadership/center-medicare-medicaid-innovation) is the Deputy Administrator and Director of the Center for Medicare and Medicaid Innovation, at the Centers for Medicare & Medicaid Services (CMS), a federal agency within the United States Department of Health and Human Services (HHS) that administers the Medicare program and works in partnership with state governments to administer Medicaid, the Children's Health Insurance Program (CHIP), and health insurance portability standards. Dr. Fowler has over 25 years of experience in both health policy and health services research. She previously served as Executive Vice President of programs at The Commonwealth Fund and Vice President for Global Health Policy at Johnson & Johnson, where she focused on health care delivery system and payment reform in the U.S. and health care systems and reform in emerging markets. She was also special assistant to President Obama on health care and economic policy at the National Economic Council. In 2008-2010, Dr. Fowler was Chief Health Counsel to Senate Finance Committee Chair, Senator Max Baucus (D-MT), where she played a critical role developing the Senate version of the Affordable Care Act. She also played a key role drafting the 2003 Medicare Prescription Drug, Improvement and Modernization Act (MMA). She also served as Vice President of Public Policy and External Affairs for WellPoint, Inc. (now Anthem), as an attorney with the Washington law firm Hogan & Hartson, and five years as a health services researcher with Park Nicollet Foundation in Minnesota. Dr. Fowler earned her bachelor’s degree from the University of Pennsylvania, where she studied the History and Philosophy of Science and Technology, a Ph.D. from the Johns Hopkins Bloomberg School of Public Health, where her research focused on risk adjustment, and a law degree (J.D.) from the University of Minnesota. She is admitted to the bar in Maryland, the District of Columbia, and the U.S. Supreme Court. Dr. Fowler is a Fellow of the inaugural class of the Aspen Health Innovators Fellowship and a member of the Aspen Global Leadership Network.

Dr. Holly Ganz, Ph.D. is Chief Science Officer And Co-Founder of AnimalBiome (https://animalbiome.com/home), a company with a goal of helping cats and dogs lead longer, happier lives by using science to unlock the mysteries of the pet gut microbiome, providing access to genetic data on the health of the gut microbiome, better ways to log health and diet records, and offering remedies to treat chronic digestive disorders. Dr. Ganz received her PhD from UC Davis Entomology and Evolutionary Ecology, an MS from the Scripps Institution of Oceanography in Marine Biology, UC San Diego and a BS in Biology from George Washington University and has studied the interaction between microbes and their hosts for over 20 years. After receiving her doctorate, she was awarded an international postdoctoral fellowship from the National Science Foundation to study how genetics affects the spread of fungal infections in animal populations in Switzerland. Subsequently she was a postdoctoral fellow at UC Berkeley studying how bacterial pathogens survive in soil to infect African wildlife. Dr. Ganz has published more than 20 papers in the peer-reviewed scientific literature.

Kathryn Coulter Mitchell (https://www.dhs.gov/person/kathryn-coulter-mitchell), is Acting Under Secretary for Science and Technology (S&T), at the U.S. Department of Homeland Security, where as the science advisor to the Homeland Security Secretary, she heads the research, development, innovation and testing and evaluation activities in support of the Department of Homeland Security’s (DHS) operational Components and first responders across the nation. The Science and Technology Directorate is responsible for identifying operational gaps, conceptualizing art-of-the-possible solutions, and delivering operational results that improve the security and resilience of the nation. In her former role as the Chief of Staff, Ms. Coulter Mitchell oversaw the operational and organizational needs of the $1 billion, 500-career-employee Directorate. A member of the Senior Executive Service, she was responsible for strategy, policy, organizational development, communications, and planning and she guided the creation of a DHS strategic vision and roadmap for research and development (R&D), the reestablishment of Integrated Product Teams to prioritize and manage DHS R&D investments, and the crafting of strategies for organizational effectiveness. Ms. Mitchell previously served S&T as Deputy Chief of Staff and Senior Communications Advisor for the Under Secretary and Deputy Under Secretary. Ms. Coulter Mitchell came to DHS after a 15-year career in the private sector and on Capitol Hill. In industry, she provided organizational strategy and communications support to the S&T directorate and the Federal Emergency Management Agency where she authored the communications strategy for the multi-million dollar, multi-agency rollout of Presidential Policy Directive 8 (This directive is aimed at strengthening the security and resilience of the United States through systematic preparation for the threats that pose the greatest risk to the security of the Nation, including acts of terrorism, cyber attacks, pandemics, and catastrophic natural disasters.) Prior to supporting the government, Ms. Coulter Mitchell was a senior-level public affairs specialist at a top Washington, D.C. public relations firm. She also served as the Director of Policy for an association of over 350 federal contracting companies. Before joining industry, Ms. Coulter Mitchell spent five years on Capitol Hill leading legislative efforts in both the U.S. House of Representatives and the U.S. Senate. Ms. Coulter Mitchell holds a Master of Arts in Communications from Johns Hopkins University, a bachelor’s degree from the University of Maryland at College Park, and a professional certification in Executive Coaching from the University of Cambridge, U.K.

Dr. Jerome H. Kim, M.D., is the Director General of the International Vaccine Institute (IVI - https://www.ivi.int/), a nonprofit International Organization established in 1997 as an initiative of the United Nations Development Programme (UNDP), dedicated to the discovery, development and delivery of safe, effective and affordable vaccines for global public health. IVI is headquartered in Seoul and hosted by the Republic of Korea with 36 member countries and the WHO on its treaty. Dr. Kim served as the Principal Deputy and Chief of the Laboratory of Molecular Virology and Pathogenesis at Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR), in addition to being the Project Manager for the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Material Development Activity. Dr. Kim was also a Professor within the Division of Infectious Diseases of the Department of Medicine at the Uniformed Services University of the Health Sciences. From 2004 – 2009 he led the Army’s Phase III HIV vaccine trial (RV144), the first demonstration that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates of protection and sequence changes in breakthrough HIV infections after vaccination. Dr. Kim graduated from the Yale University School of Medicine in 1984 and completed his training in Internal Medicine and fellowship in Infectious Diseases at Duke University Medical Center. In 2013 he received the John Maher Award for Research Excellence from the Department of Medicine, Uniformed Services University of the Health Sciences and throughout his career to date, Dr. Kim has authored over 200 publications.

Dr. Patricia Verduin, PhD, (https://www.colgatepalmolive.com/en-us/snippet/2021/circle-cards/our-leadership/patricia-verduin) is Chief Technology Officer for the Colgate-Palmolive Company where she provides leadership for product innovation, clinical science and long-term research and development across their Global Technology Centers’ Research & Development pipeline. Dr. Verduin joined Colgate Palmolive in 2007 as Vice President, Global R&D. Previously she served as Vice President, Scientific Affairs, for the Grocery Manufacturers Association, and from 2000 to 2006, she held the position of Vice President, Research & Development, at ConAgra Foods. Dr. Verduin started her career with 17 years at Nabisco, serving in multiple roles, including plant manager and scientist. She earned her undergraduate degree from the University of Delaware, holds an MBA from Fairleigh Dickinson University and a PhD in Food Science from Rutgers University. Colgate-Palmolive Company (https://www.colgatepalmolive.com/) is an American multinational consumer products company specializing in the production, distribution and provision of household, health care, personal care and veterinary products, with a mission of re-imagining a healthier future for all people, their pets and our planet.

Colonel Victor Suarez, currently serves as Commander (Chief Executive) of the 6th Medical Logistics Management Center (https://6mlmc.amedd.army.mil/), in Fort Detrick, Maryland (the U.S. Defense Department's only Medical Logistics Management Center ready to deploy in support of global and domestic operations) responsible for leading, organizing, equipping, training, maintaining, and sustaining unit subject matter expertise in medical materiel, medical maintenance and satellite communications support to the operational forces. Prior to this role, Colonel Suarez played an instrumental role as the Program Manager for the Moderna COVID-19 Vaccine at Operation Warp Speed (OWS) - a whole of government public/private partnership to rapidly deliver a safe and effective SARS-COV2 vaccine for the USA. Colonel Suarez has also served as Assistant Chief of Staff for Logistics for the US Army Regional Health Command-Atlantic managing the healthcare, PPE, lab diagnostics and medical maintenance supply chain for 14 direct reporting medical treatment facilities (medical centers, hospitals, clinics), was the Chief of Staff of the Walter Reed Army Institute of Research (WRAIR), U.S. DOD’s largest biomedical research laboratory, and was the Joint Product Manager of the Joint Vaccine Acquisition Program (JVAP), a biodefense advanced development vaccine program. Colonel Suarez graduated from UCLA with a BS in Anthropology, holds a Master of Science in Health Services Administration from Central Michigan University, Senior Service College Fellow Graduation Certificate from The George Washington University - Milken Institute School of Public Health, and is Defense Acquisition Level III certified in Science and Technology Management, Program Management and Life Cycle Logistics Defense Acquisition University. He’s also a graduate of the Tufts CSDD (Center for the Study of Drug Development) Postgraduate Course in Clinical Pharmacology, Drug Development and Regulation and the Cornell University Pharmaceutical Management Program. Colonel Suarez has served the U.S. in active military service, including a broad span of assignments from Airborne Infantry, Special Operations, Mechanized Infantry and Headquarters Department of the Army, including two combat tours as a Forward Support Medical Company Commander and Battalion Level Commander.

Olivia Zetter is Head of Government Affairs and AI Strategy at National Resilience, Inc. (https://resilience.com/) a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting bio-pharmaceutical supply chains against disruption. Founded in 2020, National Resilience, Inc. is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today, and tomorrow, can be made quickly, safely, and at scale. Olivia brings extensive experience in national security spanning diplomacy, defense, and development, along with emerging technology issues. Olivia has held multiple positions in government, most recently as a Director of Research and Analysis at the National Security Commission on Artificial Intelligence, an independent federal commission established by Congress to examine the impact of artificial intelligence on national security and defense. Olivia previously served at the Department of State as a Foreign Affairs Officer in the Office of the Coordinator for Cyber Issues, where her work spanned a diverse range of cyber policy areas. She also served as the Special Advisor on Trans-Regional Issues to the Special Presidential Envoy for the Global Coalition to Counter ISIS, where she coordinated efforts to counter the terrorist organization’s financing, foreign terrorist fighter flows, and external operations. At the Pentagon, Olivia served as a Special Assistant to the Chairman of the Joint Chiefs of Staff as part of the Chairman’s Action Group. Prior to her time in government, she worked in Washington and on-site abroad to manage stabilization and conflict management programs in the Middle East and South Asia with a U.S. government implementing partner. Olivia entered government as a Presidential Management Fellow and is the recipient of the Department of State’s Superior Honor Award. She is a Truman National Security Project Fellow. Olivia holds a Master of Public Policy from Harvard University’s Kennedy School of Government, where she was a Belfer Student Fellow, and a Bachelor of Arts in International Relations from American University.

Dr. Stephen Johnston, Ph.D. (https://biodesign.asu.edu/stephen-johnston) is the Director for the Center for Innovations in Medicine (https://biodesign.asu.edu/Research/Centers/innovations-medicine), a Professor in the School of Life Sciences, and Director of the Biological Design Graduate Program at The Biodesign Institute at Arizona State University. Dr Johnston is also Founding CEO and Chairman of the Board Of Directors of Calviri (https://calviri.com/). The Center for Innovations in Medicine and Dr. Johnston's current work focuses on innovative solutions to fundamental problems in bio-medicine, and their organization brings together a unique group of interdisciplinary scientists to identify, analyze, and come up with inventive solutions for significant un-met medical needs. Current major translational sciences and technology development projects of Dr. Johnston include 1) Cancer Eradication: with a focus on developing a universal, preventative cancer vaccine, and 2) Health Futures: with an aim of producing a diagnostic system that allows continuous monitoring of the health status of healthy people - helping in the revolution to pre-symptomatic medicine. Dr. Johnston has broad experience in basic science, including cloning the Gal4 gene, showing that proteins have separable functional domains, and discovering the ATPases Associated proteins and their role in transcription. He was also co-inventor/innovator of pathogen derived resistance, organelle transformation, the gene gun, genetic immunization, Tobacco Etch Virus protease system, expression library immunization, linear expression elements, synbodies and immunosignaturing. Dr. Johnston is author of over 150 journal articles, has over 20 patents, and has garnered approximately $85M in grant support including large programs from DARPA, NIAID and NHLBI. Dr. Johnston has a B.S. in Molecular Biology and Ph.D. in Genetics and Plant Genetics/Plant Breeding, from the University of Wisconsin-Madison, and did Postdoctoral work in Biochemistry at Penn State University Medical Center.

Sonia Arrison (https://soniaarrison.com/) is a best-selling author, analyst, entrepreneur, and investor. Sonia is founder of 100 Plus Capital (https://100pluscap.com/ - Investing in companies positively impacting human longevity), Chair of the Alliance for Longevity Initiatives (https://a4li.org/ - The first and only 501(c)(4) nonprofit organization founded with the goal of creating social and political action around the issues of combating age-related chronic conditions and increasing our number of healthy, disease-free years), co-founder of Unsugarcoat Media (acquired by Medium), and was an associate founder of Singularity University. Sonia’s research focuses on exponentially growing technologies and their impact on society. Her book, 100 Plus: How the Coming Age of Longevity Will Change Everything, From Careers and Relationships to Family and Faith, addresses the social, economic, and cultural impacts of radical human longevity, and gained national best-seller status. In addition to the Alliance for Longevity Initiatives, Sonia is a Board Member at the Thiel Foundation, Foresight Institute, and Woodland School. She is also a Senior Fellow at the Fraser Institute in Vancouver, British Columbia, and author of two previous books (Western Visions and Digital Dialog). Sonia was previously a Director and Senior Fellow in Tech Studies at the Pacific Research Institute, a columnist at TechNewsWorld, and hosted a radio show called “digital dialogue” on the Voice America network.

Raza Khan is an Engineer and Senior Market Manager for Wireless Products in Semtech’s Signal Integrity Products Group (https://www.semtech.com/products/signal-integrity), and has over 15 years of experience in the semiconductor industry. In his current role, he oversees the strategy, product line development and market development for integrated circuit (IC) solutions for optical transport needs within the wireless market. This includes the Tri-Edge™ 50G PAM4 product portfolio and ClearEdge® 25G product portfolio for the emerging 5G wireless market, as well as the FiberEdge™ 10G product portfolio for the 4G wireless market. Mr. Khan holds a Bachelor of Science degree in Electrical Engineering from Western University and a double major Masters of Business Administration in Strategic Marketing and Management of Innovation and Technology (MINT) from McMaster University. Semtech Corporation (https://www.semtech.com/) is a leading global supplier of high performance analog and mixed-signal semiconductors and advanced algorithms for infrastructure, high-end consumer and industrial equipment. Products are designed to benefit the engineering community as well as the global community. The Company is dedicated to reducing the impact it, and its products, have on the environment. Internal green programs seek to reduce waste through material and manufacturing control, use of green technology and designing for resource reduction.

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X - https://carb-x.org/) is a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, a leading cause of death around the world. 1.27 million deaths worldwide were attributed to resistant bacterial infections in 2019. The CARB-X portfolio is the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics and other products and represents the only global partnership that integrates solutions for the prevention, diagnosis and treatment of life-threatening bacterial infections, translating innovation from basic research to first-in-human clinical trials. Dr. Erin Duffy, PhD., is Chief of Research & Development at CARB-X and she has two decades of drug-discovery and problem-solving experience in the antibiotic arena. She was previously with Rib-X Pharmaceuticals (now Melinta Therapeutics) where in increasing roles she helped to build and sustain a team of researchers that translated the company’s scientific platform into next-generation and novel antibiotics that target the ribosome. Her team’s most recent achievements include the de novo design and optimization of a completely new class of antibiotics, the pyrrolocytosines, which were supported in part by CARB-X. Prior to Rib-X, Erin was the Associate Director of Innovative Discovery Technologies at Achillion Pharmaceuticals, responsible for building the structure and computational teams and platform for their antiviral efforts. She began her industrial career at Pfizer Central Research, in Groton, Connecticut, where she joined a team of computational and structural drug designers in multiple therapeutic areas. Erin was trained formally at Yale University, where she became a physical-organic chemist focused on defining computationally how small molecules interact and react in the group of Professor William L. Jorgensen. She expanded her experience to large molecules under the mentorship of Professor Axel Brunger, whose group at Yale was transitioning to a mix of computational and laboratory structural biology. Kevin Outterson, ESQ., is Executive Director of CARB-X and is a global thought leader on business models for antibiotic development and use. He is Professor of Law and N. Neil Pike Scholar of Health and Disability Law at Boston University School of Law, where he leads multi-disciplinary teams to solve global health issues. Professor Outterson is the Executive Director and Principal Investigator of CARB-X and a partner in DRIVE-AB (aka Driving Reinvestment In Research And Development And Responsible Antibiotic Use) a project composed of 15 public and 7 private partners from 12 countries that is funded by the Innovative Medicines Initiative (IMI) joint undertaking between the European Union and the European Pharmaceutical Industry Association (EFPIA). He also leads the Social Innovation on Drug Resistance program at Boston University.

Dr. Andrew Adams, Ph.D. is Vice President of Neurodegeneration Research at Eli Lilly (https://www.lilly.com/) and Co-Director of their new Lilly Institute for Genetic Medicine (https://lilly.mediaroom.com/2022-02-22-Lilly-Announces-the-Institute-for-Genetic-Medicine-and-700-Million-investment-in-Boston-Seaport-Site), a $700 million initiative to establish an institute for researching and developing genetic medicines, specifically acting at the nucleic acid level, to advance an entirely new drug class that target the root cause of diseases, an approach that is fundamentally different than medicines available today. In this role, Dr. Adams will be responsible for leading the discovery of various new types of therapies, via both internal research, and robust collaborations with external partners. These novel approaches will also allow Lilly access to previously "undruggable" targets across the breath of therapeutic areas at Lilly, as well as potentially opening up novel avenues of clinical investigation. In addition to these major roles, Dr. Adams over the recent years also took on scientific leadership of Lilly’s COVID-19 neutralizing antibody projects, as well as serving as Vice President for Lilly Genetic Medicine, and during his time at Lilly has served in roles across early discovery, external innovation, and as a leader of Lilly’s early trailblazer teams, championing new ways to bring Lilly science to patients with speed. Dr Adams holds a degree in biology and a doctorate in zoology from the University of Aberdeen, Scotland. Prior to joining Lilly in 2011, he was a postdoctoral fellow at Harvard Medical School studying the neurobiology of anorexia nervosa.

Dr. David Su, Ph.D. (https://atmosic.com/company/leadership/) is CEO and Co-Founder of Atmosic, a fascinating company that is “re-architecting” wireless connectivity solutions from the ground up to radically reduce Internet of Things (IoT) device dependence on batteries, aiming to make batteries last forever and the Internet of Things battery free – thus breaking the power barrier to widespread IoT adoption. Dr. Su brings to Atmosic over 30 years of engineering expertise with an extensive wireless background, as his past teams’ radio designs have brought billions of successful devices to market. He was on the early engineering team at Atheros, as VP Analog/RF Engineering, and VP Engineering with Qualcomm following the 2011 acquisition of Atheros. He was also at HP for several years. Dr. Su earned a Bachelor of Science (B.S.) and Master of Engineering (MEng) in Electrical Engineering, from University of Tennessee, a Ph.D. in Electrical Engineering from Stanford University, and has been a Consulting Professor of Electrical Engineering at Stanford. He is an Institute of Electrical and Electronics Engineers Fellow.

Dr. Peter J. Hotez, M.D., Ph.D. (https://peterhotez.org/), is Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology and Microbiology at Baylor College of Medicine (https://www.bcm.edu/people-search/peter-hotez-23229), where he is also Chief of the Section of Pediatric Tropical Medicine and the Texas Children’s Hospital Endowed Chair of Tropical Pediatrics (https://www.texaschildrens.org/find-a-doctor/peter-jay-hotez-md-phd). Dr. Hotez is also Rice University’s Baker Institute fellow in disease and poverty (https://www.bakerinstitute.org/experts/peter-j-hotez/) and Co-Director of Parasites Without Borders (https://parasiteswithoutborders.com/), a global nonprofit organization with a focus on those suffering from parasitic diseases in subtropical environments. Dr. Hotez is an internationally recognized physician-scientist with expertise in neglected tropical diseases and vaccine development. He leads the only product development partnership for developing new vaccines for hookworm, schistosomiasis and Chagas disease, and is just coming off a major win for emergency use approval of his team’s Corbevax protein sub-unit COVID-19 vaccine, of which he, and previous guest to the show, Dr. Maria Elena Bottazzi, were recently nominated for a Nobel Prize. Dr. Hotez is the author of more than 400 original papers, as well as the books Forgotten People, Forgotten Diseases - The Neglected Tropical Diseases and Their Impact on Global Health and Development, Blue Marble Health - An Innovative Plan to Fight Diseases of the Poor amid Wealth, Vaccines Did Not Cause Rachel's Autism: My Journey as a Vaccine Scientist, Pediatrician, and Autism Dad, and Preventing the Next Pandemic: Vaccine Diplomacy in a Time of Anti-science. Dr. Hotez previously served as president of the American Society of Tropical Medicine and Hygiene, the Sabin Vaccine Institute and as founding editor-in-chief of PLoS Neglected Tropical Diseases. He is an elected member of the Institute of Medicine (IOM) of the National Academy of Sciences. In 2011, he was awarded the Abraham Horwitz Award for Excellence in Leadership in Inter-American Health by the Pan American Health Organization of the World Health Organization. In 2015, the White House and U.S. State Department selected Dr. Hotez as a United States science envoy. Dr. Hotez obtained his undergraduate degree in molecular biophysics from Yale University (Phi Beta Kappa), followed by a Ph.D. in biochemical parasitology from Rockefeller University, and an M.D. from Weill Cornell Medical College.

Teresa Bonner is the Executive Director of the E.A. Michelson Philanthropy (https://eamichelsonphilanthropy.org/), an organization with a mission of championing programs that break barriers, build community and spark creativity, through funding and advocacy. E.A. Michelson Philanthropy has made grants totaling more than US$47 Million since 2006, actively supporting nonprofit organizations across the United States through direct financial support, advocacy, partnerships, informal alliances, convenings, trainings and more. A cornerstone of the E.A. Michelson Philanthropy initiatives is their Vitality Arts programs, which through partnerships with arts and cultural institutions, offer older adults the chance to learn new art forms while developing new friendships, exploring creativity and new accomplishments, connecting with others, building community, and demonstrating relevance, all while addressing equity, diversity, inclusion and access. Teresa has her BA in Journalism from University of North Dakota and a JD from University of Minnesota Law School and has been involved in the foundation, family foundation and charitable giving space for the last couple of decades.

Dr. Heather Haugen, Ph.D. is Vice President of Healthcare Advisory & Innovation for the Americas at NTT (https://www.global.ntt/). Dr. Haugen has deep expertise in health information technology and a passion for research and the application of those outcomes to the challenges that currently exist in healthcare. Dr. Haugen has more than 20 years of research experience in both the academic and private sectors including previously serving in roles as Chief Science Officer for Atos in their Digital Health Solutions division, and Managing Director of The Breakaway Group, A Xerox Company, leading to a unique mix of experience, including conducting rigorous research, leading development efforts based on research outcomes, and leading and developing top-performing teams. Dr. Haugen’s research and methodology is published in her latest book, Beyond Implementation: A Prescription for the Adoption of Healthcare Technology, which is the second edition and a National Bestseller. Dr. Haugen also holds a faculty position at the University of Colorado Denver- Anschutz Medical Center as the Director of Health Information Technology, where she actively mentors doctoral students and teaches courses. Dr. Haugen has a BS in Biological Sciences from University of Denver, an MS in Human Nutrition from Colorado State University, and a Ph.D. in Clinical Science-Health Information Technology from University of Colorado School of Medicine. Vito Mabrucco is the Head of Global Marketing at NTT. Previously Mr. Mabrucco was Senior Vice President, Worldwide Consulting, at IDC, a global provider of market intelligence, advisory services, and events for the IT, telecom, and consumer tech markets, where he was responsible for the geographic regions of Canada, Japan, and Asia Pacific, and has deep insight into the global Information and Communications Technology industry with a focus on the value of technology, strategic business models, key industry segments, and global market trends and directions. His insights include a strong understanding of disruptive innovation business models as well as insights into evolving global dynamics and how they apply to the overall technology industry. A thirty year veteran of the information and communications industry, Mr. Mabrucco has held senior management portfolios in Sales, Marketing, Finance, Systems and Strategic Planning with major global technology companies such as IBM, Tandem, Compaq, Dell and Cisco. Mr. Mabrucco is a graduate of the University of Waterloo, is on the board of the Information Technology Association of Canada (ITAC), and i a member of the Campaign Committee for the United Way. NTT’s Innovating for a Sustainable Future Report - https://www.global.ntt/isf/pdf/Innovating-for-a-sustainable-future.pdf NTT’s Innovation for a Sustainable Future Program - https://www.global.ntt/isf/index.html